RT Journal Article
SR Electronic
T1 A One-Minute Blood Test to Monitor Immune Responses in COVID-19 Patients and Predict Clinical Risks of Developing Moderate to Severe Symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.30.20203844
DO 10.1101/2020.09.30.20203844
A1 Chirajyoti Deb
A1 Allan N. Salinas
A1 Aurea Middleton
A1 Katelyn Kern
A1 Daleen Penoyer
A1 Rahul Borsadia
A1 Charles Hunley
A1 Vijay Mehta
A1 Laura Irastorza
A1 Devendra I. Mehta
A1 Tianyu Zheng
A1 Qun Huo
YR 2020
UL http://medrxiv.org/content/early/2020/10/02/2020.09.30.20203844.abstract
AB Coronavirus disease 2019 (COVID-19) has brought enormous loss and interruption to human life and the global economy since the first outbreak reported in China between late 2019 to early 2020, and will likely remain a public health threat in the months and years to come. Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms, however, a small percentage of the population will become severely ill, require hospitalization, intensive care, and some succumb to death. The current knowledge of COVID-19 disease progression with worsening symptom complex implicates the critical importance of identifying patients with high clinical risk compared to those who would be at lower risk for disease control and patient management with better therapeutic output. Currently no clinical test is available that can predict risk factors and immune status change at different severity scales. The immune system plays a critical role in the defense against infectious diseases. Extensive research has found that COVID-19 patients with poor clinical outcomes differ significantly in their immune responses to the virus from those who exhibit milder symptoms. We previously developed a nanoparticle-enabled blood test that can detect the humoral immune status change in animals. In this study, we applied this new test to analyze the immune response in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected statistically significant differences between COVID-19 patients with no or mild symptoms from those who developed moderate to severe symptoms. Mechanistic study suggests that these differences are associated with type 1 versus type 2 immune responses. We conclude that this new rapid test could potentially become a valuable clinical tool for COVID-19 patient risk stratification and management.Competing Interest StatementDr. Huo reports other from Nano Discovery Inc., outside the submitted work; In addition, Dr. Huo has a patent Detection of Interaction Between an Assay Substance and Blood or Blood Components for Immune Status Evaluation and Immune Related Disease Detection and Diagnosis pending.Funding StatementThis study is supported by intramural funding from Nano Discovery Inc. and Orlando Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study (OH IRB # 20.095.06) was approved by Orlando Health IRB#2.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.